

1 **Clinical characteristics and early outcomes in patients with COVID-19 treated with**
2 **tocilizumab at a United States academic center**

3
4 Casey A. Rimland,^{1a} Camille E. Morgan,^{1,2a} Griffin J. Bell,² Min K. Kim,³ Tanner
5 Hedrick,⁴ Ashley Marx,⁴ Brian Bramson,³ Heidi Swygard,³ Sonia Napravnik,^{2,3} John L.
6 Schmitz,⁵ Shannon S. Carson,⁶ William A. Fischer,⁶ Joseph J. Eron,³ Cynthia L. Gay,³
7 Jonathan B. Parr^{3*}
8 (^aContributed equally, *Corresponding)

9
10 ¹ Medical Scientist Training Program, University of North Carolina at Chapel Hill (UNC),
11 Chapel Hill, NC, USA

12 ² Department of Epidemiology, UNC Gillings School of Global Public Health, Chapel
13 Hill, NC, USA

14 ³ Division of Infectious Diseases, UNC School of Medicine, Chapel Hill, NC, USA

15 ⁴ Department of Pharmacy, UNC Medical Center, Chapel Hill, NC, USA

16 ⁵ Department of Pathology and Laboratory Medicine, UNC School of Medicine, Chapel
17 Hill, NC, USA

18 ⁶ Division of Pulmonary Diseases and Critical Care Medicine, UNC School of Medicine,
19 Chapel Hill, NC, USA

20

21

22 **Keywords:** SARS-CoV-2, tocilizumab, cytokine release syndrome, COVID-19,
23 interleukin 6 (IL-6)

24

25 **Running title:** Tocilizumab outcomes in severe COVID-19

26

27 **Abstract word count:** 48

28

29 **Manuscript word count:** 1368

30

31 * **Corresponding author:** Jonathan B. Parr, MD, MPH; 130 Mason Farm Rd, Chapel
32 Hill, NC 27599; jonathan_parr@med.unc.edu

33

34 **Author contributions:**

35 CAR, CEM extracted data, analyzed data, wrote first draft. GJB analyzed data. MKK extracted
36 data. JBP supervised the study. CAR, CEM, GJB, MKK, TH, AM, BB, SN, JLS, SSC, WAF, JJE,
37 CLG, JBP reviewed and edited the final draft.

38 **Abstract**

39 We describe early outcomes in 11 COVID-19 patients treated with the IL-6 receptor
40 inhibitor tocilizumab. While C-reactive protein decreased, neither clinical improvement
41 nor reduced temperature or oxygen requirements was observed in most patients. Our
42 findings contrast with prior reports and raise questions about tocilizumab use in severe
43 COVID-19.

44 INTRODUCTION

45 A hyperinflammatory state is a posited driver of severe COVID-19 [1]. Elevations of IL-6
46 have been described in acute respiratory distress syndrome and cytokine release
47 syndrome (CRS) [2,3]. Recently, IL-6-driven inflammation in severe COVID-19 was
48 suggested, as increased levels were associated with mortality [4]. IL-6 blockade via
49 tocilizumab, a humanized monoclonal antibody that targets the IL-6 receptor, has been
50 proposed as a treatment for COVID-19 [5].

51
52 Peer-reviewed reports of tocilizumab use for COVID-19 are largely limited to retrospective
53 case series from China [6,7] and Italy [8,9], as well as case reports [10–13]. Xu *et al.*
54 reported improved inflammatory markers, oxygen requirements, and fever in 21 patients
55 after tocilizumab treatment [6]. Luo *et al.*'s description of 15 patients included more
56 critically ill patients and more measured results, with 20% mortality [7]. A prospective,
57 open-label study from Italy reported clinical improvement and increased survival after
58 tocilizumab [8], while a second study in Italy found no significant clinical improvement or
59 mortality benefit following tocilizumab [9]. Given the paucity of data on tocilizumab use in
60 COVID-19 in the United States, we evaluated 11 patients treated with tocilizumab for
61 COVID-19. We detail their clinical characteristics before and after treatment and
62 reconsider tocilizumab use in severe COVID-19.

63

64 METHODS

65 We performed a retrospective cohort study of patients with COVID-19 treated with
66 tocilizumab at UNC Medical Center between March 21st and April 25th, 2020. Clinical

67 data was extracted from the medical record. COVID-19 was diagnosed using
68 nasopharyngeal swabs and reverse-transcriptase PCR (RT-PCR). IL-6 testing was
69 conducted at Mayo Clinic Laboratories (Rochester, MN) using an
70 electrochemiluminescence assay. Baseline IL-6 values for two patients were from a multi-
71 cytokine panel (lower-limit of detection [LOD] of 5.0 pg/mL); all others were from a
72 standalone IL-6 assay (LOD 1.8 pg/ml). Disease severity was defined according to the
73 World Health Organization (WHO) COVID-19 clinical status scale with minor modification
74 [14]. Descriptive statistics were calculated using JMP 15 and Wilcoxon signed rank test
75 performed in GraphPad Prism 8. Data was visualized using the *tidyverse* package in R
76 3.6.0. The study was approved by the UNC Institutional Review Board.

77

78 **RESULTS**

79 ***Patient population***

80 Eleven patients with confirmed SARS-CoV-2 infection treated with tocilizumab for COVID-
81 19 were identified and included. Demographic, clinical, and laboratory data are displayed
82 in **Table 1**. Six (55%) patients had an unknown exposure history. Median time from
83 symptom onset to admission was 8 days (IQR=5-11). Most patients were male (82%,
84 n=9); non-white (73%, n=8); non-substance users (82%) with a median age of 59 years
85 old (IQR=48-65). Patients had a median of 2 (IQR=1-6) comorbidities, including
86 hypertension (73%, n=8), type 2 diabetes mellitus (36%, n=4), and lung disease (27%,
87 n=3). Almost all were overweight (36%, n=4) or obese (55%, n=6). Five (46%) took an
88 angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) at
89 baseline. Seven (64%) were transferred from outside hospitals, all within one day of initial

90 presentation. Five (46%) were diagnosed with COVID-19 by SARS-CoV-2 RT-PCR as
91 outpatients prior to presentation.

92

93 ***Baseline laboratory and imaging characteristics***

94 On admission, most patients had significantly elevated inflammatory markers including
95 elevated CRP (100%, n=11/11), fibrinogen (100%, n=9/9), ferritin (80%, n=8/10), LDH
96 (88.9%, n=8/9), and D-dimer (70%, n=7/10). Most patients had normal total white blood
97 cell counts (WBC) (81.82%, n=9/11); two patients had elevated total WBC (18.2%).
98 However, almost all patients presented with low absolute lymphocyte counts (90.9%,
99 n=10/11). Several patients presented with laboratory signs of additional organ damage.
100 Four patients had abnormal troponin I levels (36.4%), five patients had elevated pro-BNP
101 (45.5%), three patients had elevated creatinine (27.3%), and two patients had both
102 elevated AST and ALT (18.2%). Almost all patients had abnormal chest imaging on
103 admission (91%, n=10).

104

105 ***Hospital course***

106 Most patients had severe or critical COVID-19 by modified WHO criteria (55%, n=6) at
107 the time of admission (**Table 1**). All patients required supplemental oxygen on admission,
108 including five (46%) via low-flow nasal cannula (LFNC, \leq 10L/min), two (18%) via high-
109 flow nasal cannula (HFNC), and four (36%) via mechanical ventilation. During the
110 observation period, eight (73%) were critically ill requiring mechanical ventilation and
111 vasopressors, one (9%) was critically ill requiring mechanical ventilation alone, one (9%)
112 with do-not-intubate status received HFNC only, and one (9%) had mild disease requiring

113 LFNC. Ten of the 11 (91%) received at least one dose of an anti-microbial or
114 immunomodulating treatment during their hospitalization.

115

116 ***Outcomes after tocilizumab***

117 Tocilizumab was administered a median of one day (IQR 1-4) from admission and nine
118 days (IQR 7-14) after symptom onset. Ten patients received a single tocilizumab dose,
119 and one received two doses. Median dosage was 7.9 mg/kg. Two of six patients with
120 available baseline IL-6 levels had low levels, one below the assay's LOD (≤ 5 pg/mL) and
121 another of 10.4 pg/mL. Four of five with available IL-6 levels after tocilizumab had IL-6
122 levels above the upper limit of quantification. IL-6 increased after tocilizumab in all four
123 patients with matched baseline and post-tocilizumab testing.

124

125 CRP and fibrinogen decreased significantly after tocilizumab (**Figure 1A**, median CRP
126 211.6 vs. 19.7 mg/L [$p=0.001$] and fibrinogen 767 vs. 420 mg/dL [$p=0.002$] pre- and 5
127 days post-tocilizumab, respectively). Other laboratory markers did not show clear trends
128 (**Figure 1B**). Temperature did not show obvious improvement (**Figure 1C**), and only
129 three (27%) showed improvement in oxygen requirements (**Figure 1D**). At end of follow-
130 up, patients were observed for a median of 17 days (range=7-34) after initial tocilizumab
131 dose. Three died (27%); five (45%) remained in the intensive care unit (ICU) on
132 mechanical ventilation, receiving vasopressors or hemodialysis; one (9%) was
133 transferred from the ICU to floor status and weaned to room air; and two (18%) were
134 discharged home without oxygen. Seven patients (64%) had minimally elevated liver
135 function tests after tocilizumab administration. Two were diagnosed with ileus and two

136 with bacterial pneumonia after tocilizumab administration; no serious adverse events
137 were observed.

138

139 **DISCUSSION**

140 While tocilizumab was recently described as a promising therapy for severe COVID-19,
141 our findings raise questions about its use in critically ill patients [7]. We report data from
142 patients with COVID-19 treated with tocilizumab at a United States academic center,
143 almost all of whom required ICU care. CRP and fibrinogen improved after tocilizumab
144 administration as previously reported [6–8], but improvement in disease severity or
145 mortality were not observed. These findings, in addition to low baseline IL-6 levels
146 observed in some patients, raise questions about tocilizumab use in patients presenting
147 with severe or critical COVID-19, especially without baseline IL-6 data.

148

149 Important differences exist between our cohort and those from China and Italy [6–9].
150 Three of four studies had few patients requiring mechanical ventilation (n=2/21, n=4/32,
151 and n=5/63 respectively) [6,8,9]; the fourth study did not report specific oxygen
152 requirements but did include more patients reported as critically ill (n=7/15) [7]. Our cohort
153 included higher rates of hypertension (73% versus 40% in Luo *et al.*, 37% in Campochiaro
154 *et al.*, and 38% in Sciascia *et al.*); a majority were overweight or obese (91%). We also
155 observed lower baseline IL-6 levels compared to those described in these cohorts,
156 although IL-6 assays were conducted in different laboratories. While Sciascia *et al.*
157 attribute observed survival benefit of tocilizumab treatment to early administration in their
158 Italian cohort [8], we did not observe the same clinical improvement, despite tocilizumab

159 administration within a median of one day of hospitalization. Our findings also
160 demonstrate the challenge of defining CRS in COVID-19, especially in the absence of
161 standardized IL-6 assays and limited data to support IL-6 thresholds for tocilizumab use.

162
163 Our findings contrast with most previous reports and do not provide clear evidence of
164 clinical improvement after tocilizumab treatment in patients with severe COVID-19.
165 Several explanations can be considered. First, our patients were more severely ill than
166 previous cohorts. It is possible tocilizumab was administered too late to offer benefit.
167 Second, our patient cohort was more racially and ethnically diverse and had more
168 comorbidities, notably obesity and hypertension, than those in China and Italy. Third,
169 improvements observed in prior, less severely ill cohorts, might have occurred as part of
170 the normal disease process, with or without tocilizumab.

171
172 In conclusion, tocilizumab reduces inflammatory markers (CRP, fibrinogen), but it is
173 unclear whether its activity leads to equally dramatic effects on clinical outcomes.
174 Randomized controlled trials are essential to determine when, or if, tocilizumab should be
175 used in severe COVID-19.

176

177 **ACKNOWLEDGMENTS**

178 The authors would like to thank the nurses; laboratory staff; and allied health providers
179 involved in the care of these patients. We also thank Carlton Moore and Hannah Little for
180 assistance with initial exploration of data.

181

182 ***Funding***

183 The authors report no designated funding for the project. CAR and CEM receive training
184 support from the University of North Carolina at Chapel Hill Medical Scientist Training
185 Program. CAR additionally receives training support from the National Institutes of Health
186 MD/PhD Partnership Program.

187


188 ***Conflicts of interest***

189 JBP reports research support outside the submitted work from Gilead Sciences and the
190 World Health Organization, and non-financial support from Abbott Laboratories. CLG
191 has received research support outside the submitted work from Viiv Healthcare and
192 Gilead Sciences. SSC reports research support outside of the submitted work from
193 Biomarck Pharmaceuticals.

194 **References**

- 195 1. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm' in
196 COVID-19. *J Infect* **2020**; 80:607–613.
- 197 2. Aisiku IP, Yamal J-M, Doshi P, et al. Plasma cytokines IL-6, IL-8, and IL-10 are
198 associated with the development of acute respiratory distress syndrome in patients
199 with severe traumatic brain injury. *Crit Care Lond Engl* **2016**; 20:288.
- 200 3. Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M.
201 CAR T cell-induced cytokine release syndrome is mediated by macrophages and
202 abated by IL-1 blockade. *Nat Med* **2018**; 24:731–738.
- 203 4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult
204 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The*
205 *Lancet* **2020**; 395:1054–1062.
- 206 5. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for
207 coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
208 *J Autoimmun* **2020**; :102452.
- 209 6. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with
210 tocilizumab. *Proc Natl Acad Sci* **2020**; :202005615.
- 211 7. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single
212 center experience. *J Med Virol* **2020**; :1–5.
- 213 8. Sciascia S, Aprà F, Baffa A, et al. Pilot prospective open, single-arm multicentre
214 study on off-label use of tocilizumab in patients with severe COVID-19. *Clin Exp*
215 *Rheumatol* **2020**; 38:529–532.
- 216 9. Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in
217 severe COVID-19 patients: a single-centre retrospective cohort study. *Eur J Intern*
218 *Med* **2020**; 76:43–49.
- 219 10. Ferrey AJ, Choi G, Hanna RM, et al. A Case of Novel Coronavirus Disease 19 in a
220 Chronic Hemodialysis Patient Presenting with Gastroenteritis and Developing
221 Severe Pulmonary Disease. *Am J Nephrol* **2020**; 51:337–342.
- 222 11. Michot J-M, Albiges L, Chaput N, et al. Tocilizumab, an anti-IL6 receptor antibody,
223 to treat Covid-19-related respiratory failure: a case report. *Ann Oncol* **2020**;
224 Available at: <https://linkinghub.elsevier.com/retrieve/pii/S0923753420363870>.
225 Accessed 5 May 2020.
- 226 12. Zhang X, Song K, Tong F, et al. First case of COVID-19 in a patient with multiple
227 myeloma successfully treated with tocilizumab. *Blood Adv* **2020**; 4:1307–1310.

- 228 13. Mihai C, Dobrota R, Schröder M, et al. COVID-19 in a patient with systemic
229 sclerosis treated with tocilizumab for SSc-ILD. *Ann Rheum Dis* **2020**; 79:668–669.
- 230 14. World Health Organization. WHO R&D Blueprint novel Coronavirus: COVID-19
231 Therapeutic Trial Synopsis. Geneva, Switzerland: 2020.



233 **Figure 1. Laboratory and clinical outcomes of patients treated with tocilizumab. (A-**
234 **B) Laboratory trends following tocilizumab. Medians (blue lines), interquartile ranges**
235 **(IQR, blue shading), and reference ranges (dashed red lines). (C-D) Oxygen**
236 **requirements and temperature trends, displayed using locally estimated scatterplot**
237 **smoothing (orange lines). Patient #6 was treated with two doses of tocilizumab; time 0**
238 **refers to the time of initial administration.**

239 **Table 1. Patients with COVID19 treated with tocilizumab demographics and**
 240 **clinical characteristics (n=11).**

Demographics and Clinical Characteristics	Median (IQR) / Percentage (n)
Age / Male sex	59 (48-65) / 82% (9)
Race	
Hispanic/Latino	46% (5)
Caucasian	27% (3)
African American	27% (3)
Tobacco / ethanol / substance use	9% (1) / 9% (1) / 9% (1)
BMI	31 (29-36)
Normal (18.5-25)	9% (1)
Overweight (25-30)	36% (4)
Obese (>30)	55% (6)
Comorbidities	
Hypertension	73% (8)
Type 2 diabetes mellitus	36% (4)
Lung disease	27% (3)
Cardiovascular disease	18% (2)
Liver disease	9% (1)
Renal disease	9% (1)
HIV	9% (1)
Active cancer	9% (1)
Solid organ transplant	9% (1)
ACE/ARB treatment	46% (5)
COVID-19 Clinical and Treatment Characteristics	
Time from symptom onset to admission	8 (5-11)
Abnormal CXR/CT on admission	91% (10)
Prone positioning while intubated	78% (7/9)
Dosage of tocilizumab (mg/kg)	7.9 (5.8-8.1)*

Other treatments

Azithromycin	64% (7)
Hydroxychloroquine	36% (4)
Ritonavir/Lopinavir	27% (3)
Steroids	27% (3)

Admission labs [#]	Median (IQR)	Percentage abnormal (n)
CRP (mg/L)	197.3 (146.8-324.9)	100% (11/11 elevated)
Fibrinogen (mg/dL)	662.0 (566-928.5)	100% (9/9 elevated)
Ferritin (ng/mL)	589.5 (389.8-1705)	80% (8/10 elevated)
LDH (U/L)	1203 (943-2122)	89% (8/9 elevated)
D-Dimer (ng/mL)	343.5 (199.5-1,203)	70% (7/10 elevated)
WBC (x10 ⁹ /L)	8.5 (5.1-9.9)	18% (2/11 elevated)
Absolute lymphocyte count (x10 ⁹ /L)	0.8 (0.6-1)	91% (10/11 reduced)
Platelet count (x10 ⁹ /L)	230 (162-382)	18% (2/11 reduced)
Troponin I (ng/mL)	<0.034 (<0.034-0.172)	36% (4/11 elevated)
Creatinine (mg/dL)	0.92 (0.7-2.53)	27% (3/11 elevated)
Pro-BNP (pg/mL)	69.7 (34.3-6,870)	46% (5/11 elevated)
AST (U/L)	51 (44-72)	46% (5/11 elevated)
ALT (U/L)	35 (30-60)	27% (3/11 elevated)

Clinical and Laboratory Outcomes

Disease severity	Admission	Highest Severity	Outcome
8 (Deceased)	---	---	27% (3)
7 (Critical, Ventilator + Organ Support)	36% (4)	73% (8)	46% (5)
6 (Critical, Ventilator)	0% (0)	9% (1)	0% (0)
5 (Severe, HFNC/NIPPV)	18% (2) ^{***}	9% (1) ^{***}	0% (0)
4 (Mild, LFNC)	36% (4)	9% (1)	0% (0)
3 (Mild, room air)	9% (1)	0% (0)	9% (1)
1-2 (Ambulatory – Discharged)	---	---	18% (2)

Other invasive therapies

Hemodialysis/CRRT	27% (3)
ECMO	9% (1)

Length of stay (days)**	18 (15-25)		
Length (days) on mechanical ventilation**	17 (12-29)		
Laboratory measures#	<i>Pre-Tocilizumab</i>	<i>Post-Tocilizumab</i>	<i>p-value</i>
CRP (mg/L)	211.6 (176.9-313.8)	19.7 (13.6-29)	0.001
Fibrinogen (mg/dL)	767 (625-862)	420 (386.3-473.5)	0.002
IL-6 (pg/mL)	30.65 (9.1–88.8)	>400 (249.4 - >400)	0.13##

241

242 * n=12 doses; one patient received tocilizumab twice.

243 ** As of date of death, date of discharge, or end date of observation period.

244 *** One patient was do not intubate status on admission, receiving only HFNC/NIPPV. Patient subsequently died.

245 # Not all patients had all laboratory values available, data representative of patients with data available.

246 ## Only four patients had matched pre- and post-Tocilizumab IL-6 levels.

247

248 Abbreviations: OSH, outside hospital; BMI, body mass index; CXR, chest x-ray; CT, computed tomography; HIV,
249 human immunodeficiency virus; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker;
250 CRP, c-reactive protein; LDH, lactate dehydrogenase; WBC, white blood cell count; BNP, b-type natriuretic peptide;
251 AST, aspartate aminotransferase; ALT, alanine aminotransferase; HFNC, high-flow nasal cannula; NIPPV, non-
252 invasive positive pressure ventilation; LFNC, low-flow nasal cannula; CRRT, continuous renal replacement therapy;
253 ECMO, extracorporeal membrane oxygenation; IL-6, interleukin-6.